Tofacitinib in juvenile idiopathic arthritis

Sarah Clarke

doi:10.1016/s0140-6736(21)01444-6

Tofacitinib in juvenile idiopathic arthritis

Sarah Clarke

Research output: Contribution to journal › Comment/debate (Academic Journal) › peer-review

6 Citations (Scopus)

Original language	English
Pages (from-to)	1943-1945
Number of pages	3
Journal	Lancet
Volume	398
Issue number	10315
Early online date	9 Nov 2021
DOIs	https://doi.org/10.1016/s0140-6736(21)01444-6
Publication status	Published - 27 Nov 2021

Bibliographical note

Funding Information:
SLNC receives support from the Wellcome Trust (203918/Z/16/Z) for a doctoral training fellowship. AVR has received speaker's fees, served on advisory boards, and received consulting fees unrelated to the topic of this Comment from AbbVie, Novartis, Roche, Swedish Orphan Biovitrum AB, and Union Chimique Belge, and serves on an advisory board or steering committee for Eli Lilly on trials of baricitinib in children with rheumatic diseases.

Access to Document

10.1016/s0140-6736(21)01444-6

Handle.net

Persistent link

Cite this

@article{c57eb50f65e64f578caeb130cd059194,

title = "Tofacitinib in juvenile idiopathic arthritis",

author = "Sarah Clarke",

note = "Funding Information: SLNC receives support from the Wellcome Trust (203918/Z/16/Z) for a doctoral training fellowship. AVR has received speaker's fees, served on advisory boards, and received consulting fees unrelated to the topic of this Comment from AbbVie, Novartis, Roche, Swedish Orphan Biovitrum AB, and Union Chimique Belge, and serves on an advisory board or steering committee for Eli Lilly on trials of baricitinib in children with rheumatic diseases.",

year = "2021",

month = nov,

day = "27",

doi = "10.1016/s0140-6736(21)01444-6",

language = "English",

volume = "398",

pages = "1943--1945",

journal = "Lancet",

issn = "0140-6736",

publisher = "Lancet Publishing Group",

number = "10315",

}

TY - JOUR

T1 - Tofacitinib in juvenile idiopathic arthritis

AU - Clarke, Sarah

N1 - Funding Information: SLNC receives support from the Wellcome Trust (203918/Z/16/Z) for a doctoral training fellowship. AVR has received speaker's fees, served on advisory boards, and received consulting fees unrelated to the topic of this Comment from AbbVie, Novartis, Roche, Swedish Orphan Biovitrum AB, and Union Chimique Belge, and serves on an advisory board or steering committee for Eli Lilly on trials of baricitinib in children with rheumatic diseases.

PY - 2021/11/27

Y1 - 2021/11/27

UR - http://dx.doi.org/10.1016/s0140-6736(21)01444-6

U2 - 10.1016/s0140-6736(21)01444-6

DO - 10.1016/s0140-6736(21)01444-6

M3 - Comment/debate (Academic Journal)

SN - 0140-6736

VL - 398

SP - 1943

EP - 1945

JO - Lancet

JF - Lancet

IS - 10315

ER -

Tofacitinib in juvenile idiopathic arthritis

Bibliographical note

Access to Document

Handle.net

Other files and links

Cite this